EXTERNAL ACTIVE GRANTS AND CONTRACTS:
PI: R01CA295996 (NIH/NCI) Wang (MPI) 8/2025-7/2030
“Targeted MDM2 degradation for improved treatment for triple-negative breast cancer”. Total cost: $3,238,801.
PI: R01CA276152-01 (NIH/NCI) Tiffany Seagroves (MPI) 4/2023-3/2028
“Targeting brain and bone metastases in metastatic breast cancer for improved patient survival”. Total direct cost $1,996,410. Total cost: $3,074,470
PI: HT9425-23-1-0216 Junming Yue (Co-PI) 7/2023-6/2027
“Development of an Orally Available and Low-Toxic Chemotherapy for Improved Ovarian Cancer Therapy”. Total cost $924,000.
MPI: 1RF1AG072703 (NIH/NIA) Liao (contact PI); Li and Bhaskar (MPIs) 4/2022-5/2027
“Validation of a novel tau clearance mechanism”. Five-year total expected cost: about $3.6 million.
Co-I: R01CA276135-01A1 (NIH/NCI) Zhou (PI) 12/1/2023-11/30/2028
“Discovery of a novel MDM2-tubulin signaling pathway as a therapeutic target in AML”, total cost $2,716,883. Amount to the Li lab: $37,553/year for a total of $187,765. Role: subcontract PI.
Co-I: 1R01NS128336-01 Ram Mahato (PI) 7/15/2022-5/31/2027
“Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma”. Total amount: $2,391,270. Amount to the Li lab: $38,115/year for a total of $190,575.
Role: subcontract PI.
Mentor and Co-I: R16GM154786-01 (NIH/NIGMS) Souvik Banerjee (PI) 7/2024-6/2028
“Discovery of fused heterocyclic pyrazine based novel anti-mitotic agents for metastatic melanoma”. Total cost: $684,757. Li lab share: $138,600.
ACTIVE INTERNAL FUNDING AND COMPLETED FUNDING:
Please see the relevant sections in the CV.